Therapeutic approaches to bone diseases.
暂无分享,去创建一个
[1] William M. O'Fallon,et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. , 1990 .
[2] J. Bidwell,et al. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. , 1995, Bone.
[3] A. Mithal,et al. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. , 1996, Endocrine reviews.
[4] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[5] Josef M. Penninger,et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.
[6] C. Dunstan. Osteoprotegerin and Osteoprotegerin Ligand Mediate the Local Regulation of Bone Resorption , 2000 .
[7] S. Teitelbaum,et al. Bone resorption by osteoclasts. , 2000, Science.
[8] Michael J. Goodman,et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women , 2000, The Lancet.
[9] N. Udagawa,et al. Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] S. Harris,et al. Stimulation of bone formation in vitro and in rodents by statins. , 1999, Science.
[11] C. Christiansen,et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.
[12] D E Griswold,et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.
[13] T. Martin,et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. , 2000, Arthritis and rheumatism.
[14] D. Yamashita,et al. Cathepsin K and the design of inhibitors of cathepsin K. , 2000, Current pharmaceutical design.
[15] B. Hollis,et al. Modulation of ovariectomy-related bone loss by parathyroid hormone in rats , 1990, Mechanisms of Ageing and Development.
[16] H. Genant,et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. , 1998, The Journal of clinical investigation.
[17] D. Copp,et al. Changes in Response to Calcitonin Following Prolonged Administration to Intact Rats , 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[18] P. Kostenuik,et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. , 2000, Cancer research.
[19] B F Boyce,et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.
[20] L. Mosekilde,et al. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model. , 1995, Bone.
[21] R. Pitti,et al. Effects of kistrin on bone resorption in vitro and serum calcium in vivo , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] H. Selye. ON THE STIMULATION OF NEW BONE-FORMATION WITH PARATHYROID EXTRACT AND IRRADIATED ERGOSTEROL , 1932 .
[23] Jeffrey Bonadio,et al. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration , 1999, Nature Medicine.
[24] J. Blangero,et al. Genetic Epidemiological Approaches to the Search for Osteoporosis Genes , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] G. Rodan,et al. Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during Apoptosis , 1999, The Journal of Biological Chemistry.
[26] D. Holt,et al. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. , 2000, Chemistry & biology.
[27] R. Turner,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1–34) on Bone Histomorphometry and Serum Chemistry in Rats* , 2022 .
[28] G. Rodan,et al. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. , 1998, The Journal of clinical investigation.
[29] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[30] T. Martin,et al. Activated T lymphocytes support osteoclast formation in vitro. , 1999, Biochemical and biophysical research communications.
[31] A. Parfitt,et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. , 1998, The Journal of clinical investigation.
[32] M A Horton,et al. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. , 1997, The Journal of clinical investigation.
[33] J. Hayman,et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. , 1991, Cancer research.
[34] R. Pacifici. Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis-The Second Decade. , 1998, Endocrinology.
[35] T. Yoneda. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. , 1998, European journal of cancer.
[36] R. Wallace,et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.
[37] Sakae Tanaka,et al. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption , 1996, Nature.
[38] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[39] Arndt F Schilling,et al. Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.
[40] R. Jilka,et al. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.
[41] J. Hayman,et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. , 1990, Cancer research.
[42] HMG-CoA reductase inhibitors and the risk of fractures. , 2000 .
[43] C. Leu,et al. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. , 1998, Endocrinology.
[44] G. Rodan,et al. Bone mass homeostasis and bisphosphonate action. , 1997, Bone.
[45] G. Rodan,et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. , 2000, Archives of biochemistry and biophysics.
[46] T. Martin,et al. Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. , 1995, Bone.
[47] G. Rodan,et al. The role of prostaglandins in bone formation. , 1995, Connective tissue research.
[48] T. Martin,et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.
[49] M. Rogers,et al. Heterocycle‐Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure‐Activity Relationships in J774 Macrophages , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[50] R. Lindsay,et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis , 1997, The Lancet.
[51] X. Liang,et al. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. , 2000, The Journal of clinical investigation.
[52] J. Milbrandt,et al. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. , 1998, The Journal of clinical investigation.
[53] B. R. Smith,et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. , 2000, The Journal of clinical investigation.
[54] I. McInnes,et al. A proinflammatory role for IL-18 in rheumatoid arthritis. , 1999, The Journal of clinical investigation.
[55] R Wieser,et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.
[56] P. Mantyh,et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.
[57] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[58] S. Rodan,et al. Sphingosine kinase mediates cyclic AMP suppression of apoptosis in rat periosteal cells. , 1998, Molecular pharmacology.
[59] J. Gustafsson,et al. Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[60] N. Athanasou,et al. Human osteoclast ontogeny and pathological bone resorption. , 1999, Histology and histopathology.
[61] J. Mönkkönen,et al. Molecular mechanisms of action of bisphosphonates. , 1999, Bone.
[62] H. Broxmeyer,et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6 , 1992 .
[63] P. Roberson,et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. , 1999, The Journal of clinical investigation.
[64] S Hulley,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.
[65] S. Cummings,et al. Do statins prevent both cardiovascular disease and fracture? , 2000, JAMA.
[66] M. Hatada,et al. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[67] Yuqiong Liang,et al. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification , 1999, Nature Genetics.
[68] C. Christiansen,et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. , 1998 .
[69] Allan Bradley,et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.
[70] Farina,et al. Selective inhibitors of the osteoclast vacuolar proton ATPase as novel bone antiresorptive agents. , 1999, Drug discovery today.
[71] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[72] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[73] W. Sly,et al. Human carbonic anhydrases and carbonic anhydrase deficiencies. , 1995, Annual review of biochemistry.
[74] T. Martin,et al. Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .
[75] N. Takahashi,et al. Glucocorticoid regulation of calcitonin receptor in mouse osteoclast‐like multinucleated cells , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[76] R. Turner,et al. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. , 1995, Endocrinology.
[77] Olof Johnell,et al. Hormone replacement therapy and risk of hip fracture: population based case-control study , 1998, BMJ.
[78] M. Ikegame,et al. Morphology of bone metastasis. , 1998, European journal of cancer.
[79] J. Pike,et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.
[80] F. Rousseau,et al. The genetics of osteoporosis: ‘complexities and difficulties’ , 2000, Clinical genetics.
[81] T. Martin,et al. Physiological levels of calcitonin regulate the mouse osteoclast calcitonin receptor by a protein kinase Alpha-mediated mechanism. , 1996, Endocrinology.
[82] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[83] H. Okamura,et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. , 1998, The Journal of clinical investigation.
[84] C. Turner,et al. Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. , 1999, Journal of medicinal chemistry.
[85] P. Fratzl,et al. Abnormal bone mineralization after fluoride treatment in osteoporosis: A small‐angle x‐ray‐scattering study , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[86] E. Nemeth,et al. Calcimimetic Compounds: a Direct Approach to Controlling Plasma Levels of Parathyroid Hormone in Hyperparathyroidism , 1999, Trends in Endocrinology & Metabolism.